凝血因子XI抑制剂研究进展

Research progress on the inhibitors against factor XI

近十几年来血栓性疾病发病率上升,严重危害人类的健康。目前临床使用的抗血栓药物存在易出血等不良反应。大量临床资料表明,先天缺乏凝血因子XI(factor XI,FXI)的患者患缺血性脑卒中及深静脉血栓的比率明显降低,且一般无自发性出血。由于FXI的这一特点,对新抗凝方案探索的目光聚焦到了FXI抑制剂的开发上。以FXI为靶点的抗血栓新药研究已取得一定进展。本文就FXI抑制剂的研究进展做一综述,以期为研究新的抗血栓药物提供思路。

The incidence of thrombotic diseases has increased in the past decade,a factor endangering human health.Currently,antithrombotic drugs used in the clinic have side effects such as inducing bleeding.Data from clinical observation indicate that congenital deficiency of factor XI(FXI)gene decreases the incidence of stroke and deep venous thrombosis,without causing spontaneous bleeding.This unique property of FXI makes it a potential new target for antithrombotic drugs development.Many studies have focused on the discovery of novel inhibitors targeting FXI.This review summarizes the research progress in searching for the inhibitors against FXI.